| Name | Title | Contact Details |
|---|
INTEGRIS Health is Oklahoma`s largest health system with hospitals, rehabilitation centers, physician clinics, mental health facilities, independent living centers and home health agencies located throughout the state. INTEGRIS Health is a not-for-profit corporation. It was organized under the laws of the state of Oklahoma for charitable, scientific and educational purposes and specifically to engage in the delivery of health-care services and related activities. INTEGRIS Health is governed by an 11 to 15-member board of directors made up of business and community leaders from across the state. It`s managed by President and Chief Executive Officer Bruce Lawrence, with the assistance of senior staff in the areas of physician services, facility operations, strategic services and finance. INTEGRIS Health is a not-for-profit corporation formed in 1983 to serve as the parent corporation for, and to provide management and administrative support to, INTEGRIS Baptist Medical Center Inc., another Oklahoma not-for-profit corporation that operates a tertiary care hospital in northwest Oklahoma City. In 1994, INTEGRIS Health merged with Baptist Healthcare of Oklahoma, an event that brought to the organization a network of outstanding rural hospitals across the state. In 1995, INTEGRIS Health merged with Southwest Medical Center, an acute-care hospital in southwest Oklahoma City. Each of these organizations brings a rich history of serving Oklahomans. INTEGRIS Health, along with these and a number of other affiliated entities, form the INTEGRIS Health system.
TRS Healthcare is a healthcare staffing company that provides temporary nursing and allied health professionals to facilities across the United States.
U.S. HealthWorks is a Valencia, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
Race Across AMerica is a Mesa, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.